CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hikma Pharmaceuticals Plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hikma Pharmaceuticals Plc
10 Portman Square
Phone: +44 2073992760p:+44 2073992760 LONDON, ENG  WIH 6AZ  United Kingdom Ticker: HIKHIK
Business Summary
Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and specialty pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Hikma Rx. It supplies hospitals across North America, Europe and the Middle East and North Africa (MENA) region with generic injectable and specialty medicines, supported by its growing global manufacturing network. It supplies branded generic and in-licensed products from its local manufacturing facilities to retail and hospital customers across the MENA region. Through Hikma Rx, it supplies oral, respiratory and other generic and specialty products to the North American market. Its manufacturing facilities in the United States (US) supply products across a broad range of therapeutic areas, including respiratory, oncology and pain management, serving customers in both the US and Canada.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes-Yes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Senior Non-Executive Chairman of the Board Victoria M.Hull 64 2/1/2026 11/1/2022
Chief Executive Officer, Executive Director Said S.Darwazah 67 2/1/2026 7/1/2007
Executive Vice Chairman of the Board, Deputy Chief Executive Officer of MENA Mazen S.Darwazah 2/1/2026 9/8/2005
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Arab Pharmaceutical Manufacturing Co Ltd P.O. Box 1695 Amman Jordan
Ste Promotion Pharmaceutique du Mghrb SA Rue 7. zone industrielle du Sahel HAD SOUALEM Morocco
Hikma Italia S.P.A Viale Certosa, 10 Pavia Italy
7 additional Subsidiary records available in full report.

Business Names
Business Name
Al Jazeera Pharmaceutical Industries Ltd.
AMKI MENA Holdings
Arab Pharmaceutical Manufacturing Co Ltd
27 additional Business Names available in full report.

General Information
Number of Employees: 9,603 (As of 12/31/2025)
Outstanding Shares: 209,572,695 (As of 8/7/2026)
Shareholders: 693
Stock Exchange: LON
Federal Tax Id: 223114571
Fax Number: +44 2073992761


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, August 16, 2026